WOMEN’S-ENTREPRENEURSHIP
In alignment with the 78th session of the United Nations General Assembly, the Women’s Entrepreneurship Accelerator (WEA) is proud to announce a pivotal event spotlighting the pressing gap in financing for women-led businesses. This initiative is a collaborative effort with WEA-participating UN agencies, Mary Kay Global, Yildiz Holding, and the Women Entrepreneurs Act initiative (WE Act) of the Women20 (W20) countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230913108266/en/
Titled “Inclusive Capital: Empowering Women Entrepreneurs on a Global Scale,” the WEA’s event at UNGA78 is a pivotal event spotlighting the pressing gap in financing for women-led businesses and aiming to foster dialogue among stakeholders in the women's entrepreneurship ecosystem. (Credit: Women’s Entrepreneurship Accelerator)
“Inclusive Capital: Empowering Women Entrepreneurs on a Global Scale”
Conference Room 2, United Nations Headquarters, NYC
Thursday 21 September 2023. Time: 6:00 pm – 8:00 pm ET
Register here
The event aims to foster dialogue among stakeholders in the women's entrepreneurship ecosystem. Discussions will revolve around the financial challenges women entrepreneurs face, the significance of inclusive investing, and the need for institutional and corporate entities to adopt a gender-inclusive perspective in their decision-making processes.
“Through the inception of the Women’s Entrepreneurship Accelerator, Mary Kay has helped carve a new path of intervention for the private sector,” said Deborah Gibbins, Chief Operating Officer, and Chief Financial Officer of Mary Kay Inc. “WEA is a groundbreaking partnership vehicle where the United Nations, public and private sectors, civil society organizations, and policy experts work together to transform the world WITH and FOR women entrepreneurs.”
The evening will commence with welcoming remarks from the executive leadership of UN Women followed by an introduction from Fulya Fraser, Chief Growth Officer at Pladis – part of the Yildiz Holding family of companies.
Two panel sessions will delve deep into the topics at hand:
- Accelerating Agenda 2030 through Women Entrepreneurship - Moderated by Virginia Littlejohn, Global Coordinator for Women Entrepreneurs Act (WE Act) designed to drive W20 action and implementation. The session will explore the "Trillion-dollar Opportunity in Supporting Women Entrepreneurs" and the potential economic impact if women-led businesses surmount financial barriers. Esteemed speakers include executive leaders from WEA UN partner agencies.
- Global Action for Women's Entrepreneurship - This session will spotlight major projects and programs in women entrepreneurship, featuring insights from international development leaders like Adriana Carvalho (W20Brazil), Wendy Teleki (World Bank), Marie-Christine Oghly (Femmes Chefs d’ Entreprise Mondiales - FCEM); Catherine Bosshart (Business and Professional Women - BPW), Anne Ravanona (Global InvestHER), Deborah Gibbins, Mary Kay Global, Lamia Kamal-Chaoui (Organisation for Economic Co-operation and Development - OECD).
The event's keynote will be delivered by Shazi Visram, Founder and CEO of Happy Family brands.
Registration is open until Sunday 17 September 2023 at 11:59 p.m. ET for in-person attendance at the UN Headquarters, NYC. For those unable to attend, the event will be streamed live on the United Nations Web TV website.
For more information and to register, click here.
About the Women’s Entrepreneurship Accelerator
The Women’s Entrepreneurship Accelerator (WEA) is a multi-stakeholder partnership on women’s entrepreneurship established during UNGA 74. It convenes six UN agencies, International Labour Organization (ILO), International Trade Centre (ITC), International Telecommunication Union (ITU), United Nations Development Programme (UNDP), United Nations Global Compact (UNGC), UN Women and Mary Kay Inc. to empower 5 million women entrepreneurs by 2030.
The ultimate goal of the initiative is to maximize the development impact of women entrepreneurship in achieving the Sustainable Development Goals (SDGs) by creating an enabling eco-system for women entrepreneurs around the world. The Accelerator exemplifies the transformational power of a multi-partnership of unique magnitude to harness the potential of women entrepreneurs.
Learn more at we-accelerate. Follow us: Twitter/X (We_Accelerator), Instagram (@we_accelerator), Facebook (@womensentrepreneurshipaccelerator), LinkedIn (@womensentrepreneurshipaccelerator)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230913108266/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom